Oxford Biomedica’s (OXB) Buy Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reiterated their buy rating on shares of Oxford Biomedica (LON:OXB) in a report published on Wednesday morning, Marketbeat Ratings reports. They currently have a GBX 950 price target on the biopharmaceutical company’s stock.

Separately, Deutsche Bank Aktiengesellschaft increased their target price on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a research report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Oxford Biomedica has an average rating of “Moderate Buy” and a consensus target price of GBX 663.67.

Oxford Biomedica Stock Up 0.2%

OXB opened at GBX 632 on Wednesday. The company has a 50 day moving average of GBX 764.42 and a 200 day moving average of GBX 661.68. The company has a market cap of £763.91 million, a PE ratio of -17.45 and a beta of 1.04. Oxford Biomedica has a 12 month low of GBX 232.50 and a 12 month high of GBX 952. The company has a current ratio of 1.89, a quick ratio of 1.67 and a debt-to-equity ratio of 322.11.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.